172 related articles for article (PubMed ID: 28118724)
1. [Circulating Levels of Estradiol in Breast Cancer Patients Treated with Aromatase Inhibitors and Their Clinical Implications].
Petráková K; Krásenská M; Valík D; Holánek M; Palácová M; Demlová R
Klin Onkol; 2016; 29 Suppl 3():S50-57. PubMed ID: 28118724
[TBL] [Abstract][Full Text] [Related]
2. [Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects].
Krásenská M
Klin Onkol; 2016; 29 Suppl 3():S39-49. PubMed ID: 28118723
[TBL] [Abstract][Full Text] [Related]
3. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
Wright JD; Desai VB; Chen L; Burke WM; Tergas AI; Hou JY; Accordino M; Ananth CV; Neugut AI; Hershman DL
Am J Obstet Gynecol; 2017 Jul; 217(1):59.e1-59.e12. PubMed ID: 28341383
[TBL] [Abstract][Full Text] [Related]
4. Resumption of menses with initiation of letrozole after five years of amenorrhea on tamoxifen: caution needed when using tamoxifen followed by aromatase inhibitors.
Hargis JB; Nakajima ST
Cancer Invest; 2006 Mar; 24(2):174-7. PubMed ID: 16537187
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer.
Pan K; Chlebowski RT
Clin Breast Cancer; 2014 Jun; 14(3):147-53. PubMed ID: 24503025
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant hormonal therapy in peri- and postmenopausal breast cancer.
Ryan PD; Goss PE
Oncologist; 2006; 11(7):718-31. PubMed ID: 16880231
[TBL] [Abstract][Full Text] [Related]
7. Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor.
Dieudonné AS; Vandenberghe J; Geerts I; Billen J; Paridaens R; Wildiers H; Neven P
Menopause; 2011 Jul; 18(7):821-4. PubMed ID: 21326118
[TBL] [Abstract][Full Text] [Related]
8. The serum estradiol concentration is the main determinant of the estradiol concentration in normal breast tissue.
Depypere HT; Bolca S; Bracke M; Delanghe J; Comhaire F; Blondeel P
Maturitas; 2015 May; 81(1):42-5. PubMed ID: 25721699
[TBL] [Abstract][Full Text] [Related]
9. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
[TBL] [Abstract][Full Text] [Related]
10. [Breast Cancer - Specifics of Gynecological Care and Counseling].
Weinberger V; Zikán M
Klin Onkol; 2016; 29 Suppl 3():S7-15. PubMed ID: 28118719
[TBL] [Abstract][Full Text] [Related]
11. [Hormone therapy in breast cancer: the end of tamoxifen?].
Delozier T
Bull Cancer; 2005 Feb; 92(2):142-50. PubMed ID: 15749643
[TBL] [Abstract][Full Text] [Related]
12. Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients.
Baumgart J; Nilsson K; Stavreus Evers A; Kunovac Kallak T; Kushnir MM; Bergquist J; Sundström Poromaa I
Climacteric; 2014 Feb; 17(1):48-54. PubMed ID: 23647561
[TBL] [Abstract][Full Text] [Related]
13. Recognizing menopause in women with amenorrhea induced by cytotoxic chemotherapy for endocrine-responsive early breast cancer.
Torino F; Barnabei A; De Vecchis L; Appetecchia M; Strigari L; Corsello SM
Endocr Relat Cancer; 2012 Apr; 19(2):R21-33. PubMed ID: 22241718
[TBL] [Abstract][Full Text] [Related]
14. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
15. Predictors of recovery of ovarian function during aromatase inhibitor therapy.
Henry NL; Xia R; Banerjee M; Gersch C; McConnell D; Giacherio D; Schott AF; Pearlman M; Stearns V; Partridge AH; Hayes DF
Ann Oncol; 2013 Aug; 24(8):2011-6. PubMed ID: 23613476
[TBL] [Abstract][Full Text] [Related]
16. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Tuxen MK; Nielsen DL; Lindberg H; Kamby C
Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
[TBL] [Abstract][Full Text] [Related]
17. The influence of endocrine treatments for breast cancer on health-related quality of life.
Buijs C; de Vries EG; Mourits MJ; Willemse PH
Cancer Treat Rev; 2008 Nov; 34(7):640-55. PubMed ID: 18514425
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant endocrine therapy for perimenopausal women with early breast cancer.
Ortmann O; Cufer T; Dixon JM; Maass N; Marchetti P; Pagani O; Pronzato P; Semiglazov V; Spano JP; Vrdoljak E; Wildiers H
Breast; 2009 Feb; 18(1):2-7. PubMed ID: 19036588
[TBL] [Abstract][Full Text] [Related]
19. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy with aromatase inhibitors for postmenopausal women with early breast cancer: evidence and ongoing controversy.
Wheler J; Johnson M; Seidman A
Semin Oncol; 2006 Dec; 33(6):672-80. PubMed ID: 17145347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
